Everyone
Deserves To Be Well

To satisfy my capstone class requirements for a Public Health degree at the University of North Carolina at Wilmington, I…

Our partner Cytokinetics, Incorporated announced August 2, 2021 that COURAGE-ALS, a Phase 3 clinical trial of Reldesemtiv in patients with ALS, is open to enrollment.

We are cost-conscious, financially responsible, and considerate of budgets, yet understand and clearly communicate how additional activities could add value and reduce time to market.